- Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
On 6ix: 6ix.com/news/mirum-pharmaceuticals-announces-positive-chmp-opinion-livmarlir-maralixibat-oral
Watch Mirum Pharmaceuticals' latest callMirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings CallMirum Pharmaceuticals, Inc. on 6ix
Story so far
- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
- Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
Earlier from Mirum Pharmaceuticals
- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
- Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
- Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
Later from Mirum Pharmaceuticals
- Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
- Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
- Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
- Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
Follow Mirum Pharmaceuticals into a list and get an email when it puts out news.
Follow Mirum Pharmaceuticals